A clinical study is to compare levels of C-reactive protein (CRP) as a marker of inflammation before and after initiation of elexacaftor/tezacaftor/ivacaftor (ETI) treatment in adults with stable cystic fibrosis
Latest Information Update: 21 Jul 2022
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
Most Recent Events
- 21 Jul 2022 New trial record